387 results on '"Hsi E"'
Search Results
2. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
3. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)
4. Assessment of semi‐quantitative grading of red blood cell abnormalities utilizing images from the CellaVision DM96 compared to manual light microscopy
5. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium
6. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma
7. PRPF8 defects cause missplicing in myeloid malignancies
8. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
9. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
10. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML
11. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation
12. CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)
13. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen
14. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival
15. Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma
16. Syngeneic graft-versus-host disease: a report of two cases and literature review
17. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma
18. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
19. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
20. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
21. Is there a role for folate determinations in current clinical practice in the USA?
22. Guidelines for HER2 testing in the UK
23. Absence of t(14,18) chromosomal translocation in primary cutaneous B-cell lymphoma
24. Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features
25. SURFACE IMMUNOGLOBULIN POSITIVE TRANSITIONAL PRE-B-CELL LYMPHOBLASTIC LYMPHOMA (LBL) PRESENTING AS CUTANEOUS LESIONS IN A 5 MONTH OLD
26. A NEW CD 7 PARAFFIN REACTIVE ANTIBODY AND T-γ PCR MONOCLONALITY ARE SENSITIVE AND SPECIFIC FOR A DIAGNOSIS OF MYCOSIS FUNGOIDES (MF)
27. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma
28. Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience
29. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
30. Erratum: Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
31. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy
32. 2016 WHO Classification update-What's new in lymphoid neoplasms
33. Transcription factor SPZ1 promotes TWIST-mediated epithelial–mesenchymal transition and oncogenesis in human liver cancer
34. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34)
35. ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment
36. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma
37. Molecular analysis of T cell receptor clonotypes in LGL- A clonal model for polyclonal responses
38. Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large Bcell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy:A Report from the International DLBCL Rit
39. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
40. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium
41. The Concept of Phenotypic Deviation: A Multiparameter Approach for Biologic Prognostic Markers in FL
42. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin
43. PRPF8 defects cause missplicing in myeloid malignancies
44. 16 - ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment
45. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study
46. P-030 Novel mutations in spliceosomal gene PRPF8 show ring sideroblast phenotype in patients with myeloid neoplasms
47. 1171 MICRORNA EXPRESSION PROFILING IN PERIPHERAL BLOOD MONONUCLEAR CELLS IDENTIFIES TWO MIRNAS ASSOCIATED WITH TREATMENT RESPONSE TO PEGINTERFERON-RIBAVIRIN IN CHRONIC HEPATITIS C VIRUS PATIENTS
48. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy
49. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
50. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.